PortfoliosLab logoPortfoliosLab logo
IMCR vs. CRSP
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

IMCR vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Immunocore Holdings plc (IMCR) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IMCR achieves a -17.46% return, which is significantly lower than CRSP's -0.69% return.


IMCR

1D
-3.08%
1M
0.46%
YTD
-17.46%
6M
-24.37%
1Y
-25.85%
3Y*
-20.19%
5Y*
-6.01%
10Y*

CRSP

1D
0.12%
1M
-2.80%
YTD
-0.69%
6M
-6.98%
1Y
36.91%
3Y*
-7.12%
5Y*
-14.40%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

IMCR vs. CRSP - Yearly Performance Comparison


2026 (YTD)20252024202320222021
IMCR
Immunocore Holdings plc
-17.46%17.66%-56.82%19.71%66.68%-20.74%
CRSP
CRISPR Therapeutics AG
-0.69%33.23%-37.12%54.00%-46.36%-55.11%

Correlation

The correlation between IMCR and CRSP is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.29

Correlation (3Y)
Calculated over the trailing 3-year period

0.29

Correlation (5Y)
Calculated over the trailing 5-year period

0.32

Correlation (All Time)
Calculated using the full available price history since Feb 8, 2021

0.32

Fundamentals

Market Cap

IMCR:

$1.52B

CRSP:

$5.00B

EPS

IMCR:

-$0.37

CRSP:

-$6.24

PS Ratio

IMCR:

3.79

CRSP:

1.16K

PB Ratio

IMCR:

3.85

CRSP:

2.76

Total Revenue (TTM)

IMCR:

$385.76M

CRSP:

$4.10M

Gross Profit (TTM)

IMCR:

$381.15M

CRSP:

-$171.17M

EBITDA (TTM)

IMCR:

-$3.01M

CRSP:

-$509.21M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Immunocore Holdings plc

CRISPR Therapeutics AG

Return for Risk

IMCR vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMCR
IMCR Risk / Return Rank: 1111
Overall Rank
IMCR Sharpe Ratio Rank: 1212
Sharpe Ratio Rank
IMCR Sortino Ratio Rank: 1313
Sortino Ratio Rank
IMCR Omega Ratio Rank: 1515
Omega Ratio Rank
IMCR Calmar Ratio Rank: 88
Calmar Ratio Rank
IMCR Martin Ratio Rank: 55
Martin Ratio Rank

CRSP
CRSP Risk / Return Rank: 5858
Overall Rank
CRSP Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
CRSP Sortino Ratio Rank: 6060
Sortino Ratio Rank
CRSP Omega Ratio Rank: 5656
Omega Ratio Rank
CRSP Calmar Ratio Rank: 5959
Calmar Ratio Rank
CRSP Martin Ratio Rank: 5555
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IMCR vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Immunocore Holdings plc (IMCR) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IMCRCRSPDifference
Sharpe ratioReturn per unit of total volatility

-1.29

Sortino ratioReturn per unit of downside risk

-2.18

Omega ratioGain probability vs. loss probability

0.90

1.15

-0.25

Calmar ratioReturn relative to maximum drawdown

-0.85

0.88

-1.73

Martin ratioReturn relative to average drawdown

-1.52

1.49

-3.01

IMCR vs. CRSP - Sharpe Ratio Comparison

The current IMCR Sharpe Ratio is -0.69, which is lower than the CRSP Sharpe Ratio of 0.60. The chart below compares the historical Sharpe Ratios of IMCR and CRSP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


IMCRCRSPDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.69

0.60

-1.29

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.12

-0.24

+0.12

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.14

0.23

-0.36

Drawdowns

IMCR vs. CRSP - Drawdown Comparison

The maximum IMCR drawdown since its inception was -67.45%, smaller than the maximum CRSP drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for IMCR and CRSP.


Loading charts...

Drawdown Indicators


IMCRCRSPDifference

Max Drawdown

Largest peak-to-trough decline

-67.45%

-85.11%

+17.66%

Max Drawdown (1Y)

Largest decline over 1 year

-30.60%

-42.25%

+11.65%

Max Drawdown (3Y)

Largest decline over 3 years

-67.45%

-64.91%

-2.54%

Max Drawdown (5Y)

Largest decline over 5 years

-67.45%

-80.68%

+13.23%

Current Drawdown

Current decline from peak

-61.98%

-75.20%

+13.22%

Average Drawdown

Average peak-to-trough decline

-36.56%

-49.17%

+12.61%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.42%

24.92%

-7.50%

Volatility

IMCR vs. CRSP - Volatility Comparison

The current volatility for Immunocore Holdings plc (IMCR) is 11.53%, while CRISPR Therapeutics AG (CRSP) has a volatility of 14.90%. This indicates that IMCR experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IMCRCRSPDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.53%

14.90%

-3.37%

Volatility (6M)

Calculated over the trailing 6-month period

26.30%

42.49%

-16.19%

Volatility (1Y)

Calculated over the trailing 1-year period

37.66%

61.68%

-24.02%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

50.37%

60.46%

-10.09%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

54.40%

64.27%

-9.87%

Dividends

IMCR vs. CRSP - Dividend Comparison

Neither IMCR nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

IMCR vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Immunocore Holdings plc and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B20222023202420252026
106.68M
1.46M
(IMCR) Total Revenue
(CRSP) Total Revenue
Values in USD except per share items

Frequently Asked Questions


IMCR and CRSP have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CRSP has higher volatility (14.90%) compared to IMCR (11.53%). In terms of maximum drawdown, IMCR dropped -67.45% vs CRSP's -85.11%.

CRSP currently has the higher Sharpe Ratio (0.60 vs -0.69), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IMCR and CRSP

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer